Newsroom
Zhifei Attends 2023 World Lung Health Conference and Visits World Heal...
Zhifei Attends 2023 World Lung Health Conference and Visits World Health Organization
2023-12-27
From November 15th to 18th, the Union World Conference on Lung Health, the most prestigious academic conference in the field of global tuber...
see details 》
Zhifei and GSK reached strategic cooperation, adding a new blockbuster...
Zhifei and GSK reached strategic cooperation, adding a new blockbuster product
2023-10-12
On October 8, 2023, Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as "Zhifei") and GlaxoSmithKline (GSK Biologica...
Zhifei Longcom Recombinant COVID-19 Vaccine Receives Marketing Approva...
Zhifei Longcom Recombinant COVID-19 Vaccine Receives Marketing Approval in Kenya
2022-12-23
On December 22, the Company's Recombinant COVID-19 Vaccine (CHO Cell) was approved for marketing by the Pharmacy and Poisons Board (PPB) of...
ZhiFeiShengWu and Cytiva Signed a Strategic Cooperation Agreement to Further Cooperation2020-11-09
On November 8, 2020, at the Third International Import Expo 2020 held in Shanghai, China, Zhifei and Cytiva formally signed a strategic coop...
The Mayor of Hefei City, Ling Yun and the Leaders of Relevant Departments Visited the Company2020-10-28
On October 27, accompanied by leaders of relevant departments, the mayor of Hefei city, Ling Yun and the leaders of relevant departments vis...
ZhiFeiShengWu Listed in the "2020 China's Top 500 Manufacturing Private Enterprises"2020-09-11
On September 10, the 2020 China Top 500 Private Enterprises Summit hosted by the All-China Federation of Industry and Commerce was held in ...
Unveiling Ceremony of "Hunan Province Vaccine Clinical Trial Demonstration Base" Held2020-08-10
On the morning of August 10, the unveiling ceremony of Hunan Vaccine Clinical Trial Demonstration Base jointly constructed by Hunan CDC and ...
Zhifei Initiated Phase II Clinical Trials of Recombinant 2019-nCoV Vaccine2020-07-10
On July 10, the Phase II clinical trials of recombinant 2019-nCoV vaccine jointly developed by Zhifei Longcom, a wholly-owned subsidiary of ...